Intravenous Bone Marrow Mononuclear Cells for Acute Ischemic Stroke: Safety, Feasibility, and Effect Size from a Phase I Clinical Trial

Cellular therapy is a promising investigational modality to enhance poststroke recovery. We conducted a single‐arm, phase I clinical trial to determine the safety and feasibility of intravenous (IV) administration of autologous bone marrow mononuclear cells (MNCs) after acute ischemic stroke (AIS)....

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Stem cells (Dayton, Ohio) Ročník 37; číslo 11; s. 1481 - 1491
Hlavní autori:	Vahidy, Farhaan S., Haque, Muhammad E., Rahbar, Mohammad H., Zhu, Hongjian, Rowan, Paul, Aisiku, Imoigele P., Lee, Dean A., Juneja, Harinder S., Alderman, Susan, Barreto, Andrew D., Suarez, Jose I., Bambhroliya, Arvind, Hasan, Khader M., Kassam, Mallikarjuna Rao, Aronowski, Jaroslaw, Gee, Adrian, Cox, Charles S., Grotta, James C., Savitz, Sean I.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Hoboken, USA John Wiley & Sons, Inc 01.11.2019 Oxford University Press
Predmet:	Acute brain injury Autografts Bone marrow Bone marrow cells Brain oschemia Clinical trials Confidence intervals Dosage Feasibility Intravenous administration Ischemia Leukocytes (mononuclear) Neurological rehabilitation Regenerative medicine Safety Secondary analysis Stem cells Stroke Stroke Regenerative medicine Neurological rehabilitation Stem cells Acute brain injury Bone marrow cells Brain oschemia
ISSN:	1066-5099, 1549-4918, 1549-4918
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!